vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与GIBRALTAR INDUSTRIES, INC.（ROCK）财务数据对比。点击上方公司名可切换其他公司
GIBRALTAR INDUSTRIES, INC.的季度营收约是CATALYST PHARMACEUTICALS, INC.的1.5倍（$225.0M vs $152.6M），GIBRALTAR INDUSTRIES, INC.同比增速更快（24.9% vs 7.6%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $26.2M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs -12.3%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
直布罗陀工业公司是专业建筑、基础设施及可再生能源产品制造商与分销商，主营通风系统、屋面配件、太阳能安装支架、园林景观产品等，主要服务北美地区住宅、商业建筑及清洁能源市场，专注提供创新可持续的客户解决方案。
CPRX vs ROCK — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $225.0M |
| 净利润 | $52.7M | — |
| 毛利率 | 82.9% | 25.3% |
| 营业利润率 | 40.5% | 7.9% |
| 净利率 | 34.5% | — |
| 营收同比 | 7.6% | 24.9% |
| 净利润同比 | -5.8% | — |
| 每股收益（稀释后） | $0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | $225.0M | ||
| Q3 25 | $148.4M | $310.9M | ||
| Q2 25 | $146.6M | $309.5M | ||
| Q1 25 | $141.4M | $290.0M | ||
| Q4 24 | $141.8M | $180.1M | ||
| Q3 24 | $128.7M | $277.1M | ||
| Q2 24 | $122.7M | $273.6M | ||
| Q1 24 | $98.5M | $292.5M |
| Q4 25 | $52.7M | — | ||
| Q3 25 | $52.8M | $-89.1M | ||
| Q2 25 | $52.1M | $26.0M | ||
| Q1 25 | $56.7M | $21.1M | ||
| Q4 24 | $55.9M | — | ||
| Q3 24 | $43.9M | $34.0M | ||
| Q2 24 | $40.8M | $32.2M | ||
| Q1 24 | $23.3M | $24.9M |
| Q4 25 | 82.9% | 25.3% | ||
| Q3 25 | 84.7% | 26.6% | ||
| Q2 25 | 85.9% | 28.4% | ||
| Q1 25 | 87.3% | 26.8% | ||
| Q4 24 | 84.7% | 29.0% | ||
| Q3 24 | 85.0% | 29.4% | ||
| Q2 24 | 87.4% | 30.5% | ||
| Q1 24 | 87.3% | 28.9% |
| Q4 25 | 40.5% | 7.9% | ||
| Q3 25 | 44.7% | 12.8% | ||
| Q2 25 | 45.2% | 12.8% | ||
| Q1 25 | 44.8% | 8.8% | ||
| Q4 24 | 44.3% | 13.3% | ||
| Q3 24 | 39.6% | 15.6% | ||
| Q2 24 | 44.2% | 14.9% | ||
| Q1 24 | 27.5% | 10.8% |
| Q4 25 | 34.5% | — | ||
| Q3 25 | 35.6% | -28.6% | ||
| Q2 25 | 35.6% | 8.4% | ||
| Q1 25 | 40.1% | 7.3% | ||
| Q4 24 | 39.4% | — | ||
| Q3 24 | 34.1% | 12.3% | ||
| Q2 24 | 33.2% | 11.8% | ||
| Q1 24 | 23.6% | 8.5% |
| Q4 25 | $0.40 | — | ||
| Q3 25 | $0.42 | $-2.98 | ||
| Q2 25 | $0.41 | $0.87 | ||
| Q1 25 | $0.45 | — | ||
| Q4 24 | $0.44 | — | ||
| Q3 24 | $0.35 | $1.11 | ||
| Q2 24 | $0.33 | $1.05 | ||
| Q1 24 | $0.19 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $115.7M |
| 总债务越低越好 | — | $0 |
| 股东权益账面价值 | $954.3M | $950.4M |
| 总资产 | $1.1B | $1.4B |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | $115.7M | ||
| Q3 25 | $689.9M | $89.4M | ||
| Q2 25 | $652.8M | $43.3M | ||
| Q1 25 | $580.7M | $25.1M | ||
| Q4 24 | $517.6M | $269.5M | ||
| Q3 24 | $442.3M | $228.9M | ||
| Q2 24 | $375.7M | $179.1M | ||
| Q1 24 | $310.4M | $146.7M |
| Q4 25 | — | $0 | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $0 | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 |
| Q4 25 | $954.3M | $950.4M | ||
| Q3 25 | $920.2M | $951.8M | ||
| Q2 25 | $856.0M | $1.0B | ||
| Q1 25 | $794.3M | $1.0B | ||
| Q4 24 | $727.6M | $1.0B | ||
| Q3 24 | $660.9M | $1.0B | ||
| Q2 24 | $608.7M | $975.7M | ||
| Q1 24 | $561.4M | $940.2M |
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $971.9M | $1.5B | ||
| Q1 25 | $908.9M | $1.4B | ||
| Q4 24 | $851.4M | $1.4B | ||
| Q3 24 | $772.0M | $1.4B | ||
| Q2 24 | $706.4M | $1.4B | ||
| Q1 24 | $646.7M | $1.3B |
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $35.5M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $26.2M |
| 自由现金流率自由现金流/营收 | 29.4% | 11.7% |
| 资本支出强度资本支出/营收 | 0.0% | 4.1% |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | $120.6M |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | $35.5M | ||
| Q3 25 | $32.4M | $73.0M | ||
| Q2 25 | $71.3M | $44.9M | ||
| Q1 25 | $60.0M | $13.7M | ||
| Q4 24 | $70.9M | $19.9M | ||
| Q3 24 | $72.9M | $64.7M | ||
| Q2 24 | $64.1M | $36.5M | ||
| Q1 24 | $31.9M | $53.2M |
| Q4 25 | $44.9M | $26.2M | ||
| Q3 25 | — | $64.8M | ||
| Q2 25 | $71.3M | $27.3M | ||
| Q1 25 | — | $2.3M | ||
| Q4 24 | $70.8M | $14.1M | ||
| Q3 24 | $72.6M | $60.5M | ||
| Q2 24 | $64.1M | $33.5M | ||
| Q1 24 | $31.7M | $48.8M |
| Q4 25 | 29.4% | 11.7% | ||
| Q3 25 | — | 20.8% | ||
| Q2 25 | 48.6% | 8.8% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | 49.9% | 7.8% | ||
| Q3 24 | 56.4% | 21.8% | ||
| Q2 24 | 52.3% | 12.2% | ||
| Q1 24 | 32.2% | 16.7% |
| Q4 25 | 0.0% | 4.1% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 0.0% | 5.7% | ||
| Q1 25 | 0.0% | 3.9% | ||
| Q4 24 | 0.1% | 3.3% | ||
| Q3 24 | 0.2% | 1.5% | ||
| Q2 24 | 0.0% | 1.1% | ||
| Q1 24 | 0.2% | 1.5% |
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 1.37× | 1.73× | ||
| Q1 25 | 1.06× | 0.65× | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | 1.90× | ||
| Q2 24 | 1.57× | 1.13× | ||
| Q1 24 | 1.37× | 2.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
ROCK
| Transferred At Point In Time | $183.5M | 82% |
| Infrastructure | $22.5M | 10% |
| Other | $18.9M | 8% |
